Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides
- PMID: 12797542
- DOI: 10.1023/a:1023361912950
Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides
Abstract
Inadequate immune response to infectious danger may contribute to the pathogenesis of systemic autoimmune diseases, e.g., systemic lupus erythematosus. To test this hypothesis, we studied innate responses of prediseased lupus-prone Palmerston North (PN) mice to lipopolysaccharide (LPS), bacterial DNA, and synthetic CpG oligonucleotides. LPS and bacterial DNA/CpG oligodeoxyribonucleotides (ODNs) drove PN splenocytes into the cell cycle and protected B cells against spontaneous apoptosis, as in control lupus-free DBA-1 mice. LPS induced significantly higher IL-6 production in PN than in control splenocytes. In contrast, in PN splenocytes bacterial DNA and CpG ODNs induced approximately four- to sixfold lower IL-12p40 and approximately twofold lower IL-6 secretion than controls. This reduction in cytokine secretion in PN mice was not due to delayed kinetics but was related to significantly higher constitutive and CpG-inducible IL-10 secretion. Neutralizing anti-IL-10 antibodies almost completely restored PN IL-6 and IL-12p40 secretion to DBA-1 levels, whereas exogenous IL-10 inhibited in vitro IL-6 and IL-12p40 production in DBA-1 mice. Importantly, treatment with either IL-10 or anti-IL-10 antibody did not modulate CpG-induced cell cycle entry and apoptosis protection in either strain. In conclusion, lupus-prone PN mice show abnormal innate responses through their pattern-recognition TLR9 receptors, characterized by higher inducible IL-10 and lower IL-12p40 and IL-6 secretion, thus implying that response to infectious danger in PN mice is inappropriate and may be linked to lupus pathogenesis.
Similar articles
-
Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?Clin Exp Immunol. 2005 Apr;140(1):1-10. doi: 10.1111/j.1365-2249.2004.02728.x. Clin Exp Immunol. 2005. PMID: 15762869 Free PMC article. Review.
-
TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production.J Clin Immunol. 2005 Jan;25(1):29-40. doi: 10.1007/s10875-005-0355-6. J Clin Immunol. 2005. PMID: 15742155
-
IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA.J Immunol. 2004 Jan 15;172(2):954-63. doi: 10.4049/jimmunol.172.2.954. J Immunol. 2004. PMID: 14707068
-
Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides.J Immunol. 2005 Feb 15;174(4):2429-34. doi: 10.4049/jimmunol.174.4.2429. J Immunol. 2005. PMID: 15699180
-
A Toll for lupus.Lupus. 2005;14(6):417-22. doi: 10.1191/0961203305lu2102rr. Lupus. 2005. PMID: 16038103 Review.
Cited by
-
Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus.Arthritis Res Ther. 2006;8(1):203. doi: 10.1186/ar1888. Epub 2006 Jan 10. Arthritis Res Ther. 2006. PMID: 16542467 Free PMC article. Review.
-
Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?Clin Exp Immunol. 2005 Apr;140(1):1-10. doi: 10.1111/j.1365-2249.2004.02728.x. Clin Exp Immunol. 2005. PMID: 15762869 Free PMC article. Review.
-
Autoantibodies in systemic lupus erythematosus.Pediatr Nephrol. 2012 Oct;27(10):1855-68. doi: 10.1007/s00467-011-2078-4. Epub 2011 Dec 23. Pediatr Nephrol. 2012. PMID: 22193636 Review.
-
TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production.J Clin Immunol. 2005 Jan;25(1):29-40. doi: 10.1007/s10875-005-0355-6. J Clin Immunol. 2005. PMID: 15742155
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical